Anne McDonald Pritchett, PhD

@RxPricing PBMs are the problem not patents. PBMs use tactics like preferential formulary placement of branded biologics over biosimilars, complex rebate structures, and exclusive contracts to limit the inclusion of biosimilars in insurance plans.

As more biologics enter the Rx drug market, greater biosimilar competition is especially critical to bringing down costs for patients, taxpayers and the U.S. health care system. Learn more about Big Pharma’s egregious abuse of the patent system that blocks this competition:

NEW article in @IPwatchdog: Joseph Allen from @BayhDole warns that weakening patents & the Bayh-Dole Act would negatively impact startup companies that play a critical role in driving American innovation and global competitiveness: ipwatchdog.com/2026/05/14/bew…

Read @Council4IP's latest Inventor Spotlight to learn more about the women who created the first sports bra (yes—it was a game-changer) and expanded opportunities for women in sports. Check it out here: c4ip.org/inventor-spotl…

ICYMI: New op-ed in @thehill highlights how strong IP rights sustain & drive American competitiveness & explains the Special 301 Report’s role in identifying trade actions needed to ensure a level playing field for U.S. innovators. Read it here: thehill.com/opinion/intern…

Great piece by Joseph Allen in @AUTM providing insights into the role of strong IP rights & tech transfer policies like the Bayh-Dole Act. Public-private R&D partnerships that drive U.S. innovation & competitiveness rely on this policy framework. autm.net/autm-net/about…

America's innovation leadership depends on strong IP protections at home and abroad. @USIJorg's new blog breaks down key takeaways from this year's Special 301 Report which identifies actions needed to defend IP rights of U.S. innovators abroad: linkedin.com/pulse/takeaway…

Important comments on the role of strong IP protections in attracting R&D investment & driving research activity that sustains & grows economies. Yet another reason why IP should be a U.S. strategic priority.

@RxPricing Generics, biosimilars, & brand to brand competition have resulted in billions in savings for patients. Patent rights have incentivized the costly & risky R&D that has led to hundreds of medical advances post-approval. Why not shed light on PBM abuses driving up patient costs?

Big Pharma deploys a full suite of tactics designed to game the U.S. patent system, enabling brand name drug companies to extend monopolies over their biggest money-makers. Learn more on how biosimilar competition reduces prescription drug costs and generates savings:

IP is the backbone of U.S. innovation. Learn more from @Council4IP with their look back at inventions patented in April that continue to shape everyday life today: c4ip.org/this-month-in-…

NEW @CFIFonline podcast featuring @ProfKOsenga on how strong patent protections drive investment and innovation & the role of injunctions in patent litigation. The podcast also addresses key myths about patents. ipprotectionmatters.org/episodes/a4414…

NEW: @CenterforIP's podcast talks about the role strong IP protections have played in fueling the $370 billion character licensing industry that supports innovative content with a global reach. buzzsprout.com/1537696/episod…

ICYMI: @BayhDole has released its 2026 Faces of American Innovation report. Read the report & you will be inspired by their stories & the innovations they brought to life: bayhdolecoalition.org/wp-content/upl…

@CSIS @CSISHealth An angle not addressed is the threats to U.S. and global public health from cuts in vaccine funding not just to Gavi but through WHO, USAID, and federal funded vaccine research & their potential to undermine economic and national security should we see another global pandemic

"U.S.-based vaccine manufacturers provide a significant share of vaccine products sold domestically and overseas, including the HPV vaccine; measles, mumps, & rubella vaccine," and more, writes @CSISHealth. Read: csis.org/analysis/10-ch…

@statnews The gold standard of the FDA is only further undermined by the politicalization of the review and approval of new medicines. FDA approval decisions should ONLY be based on a rigorous, evidence-based process that focuses on safety and effectiveness.

#Breaking: Sanofi asks to pull diabetes drug out of FDA voucher program after political appointee interfered with review trib.al/vKd1icR

@statnews Agree on the short- and long-term negative implications for U.S. public health and by extension U.S. economic and national security of leaving the WHO.

Leaving the WHO means the U.S. lacks access to necessary information about infectious disease. trib.al/SJFlIVH

Important read from ITIF highlighted by AAU--failing to step up federal support for STEM research means the U.S. will fall further behind China and Europe leading top researchers to follow the research dollars outside the U.S. to the detriment of U.S. innovation and our economy.

Breaking News: The FDA has blocked publication of research that found widely used Covid-19 and shingles vaccines were safe. nyti.ms/49dtF24

@IMAKglobal You continue to ignore the value of new medical advances resulting from continued R&D and continue to ignore the role of PBM abuses in driving up costs for patients. Without IP and other incentives, you'd never see the scientific breakthroughs needed to address unmet needs.

In our new brief, "The Monopoly Extension Menu," we examine three of Medicare's most expensive drugs to show why Medicare negotiations must be paired with patent reform to deliver low drug prices to American patients. reports.i-mak.org/monopoly-exten…

The primary patents on the cancer drug Pomalyst expired in 2019. While patients in Europe have had access to generics since early 2024, the U.S. did not have any generics until last month because Bristol Myers Squibb has used a menu of patenting schemes to keep them out. BMS has extracted billions from the U.S. healthcare system during these additional, unjustified years of monopoly. In 2024 alone, Medicare, the largest purchaser of drugs in the U.S., spent a staggering $150,095 per patient. Medicare has used its newly-granted negotiating authority to lower the price it pays for Pomalyst starting next year but even that price is nearly six times what patients pay in European countries with generic competition.

@IMAKglobal Yet you ignore that very few pay list price, ignore the significant medical advances for patients resulting from post-approval R&D, and ignore that a generic competitor's copay card means many commercially insured patients pay as little as $0.

If there were real competition, prices would fall. Instead, the list price of Revlimid is the highest it’s ever been — over $892 a pill.

Why is the price of the cancer drug Revlimid increasing even though lower-cost generics are on the market? Because Celgene/BMS used a new kind of “pay-for-delay” deal that is harder for regulators to catch: a “limited-volume settlement.”

@Council4IP's Inventor Spotlight focuses on Alexander Graham Bell and how patents helped bring the telephone to life and drive world-changing innovation. Read more: c4ip.org/inventor-spotl…